Date: 2016-03-11
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Genentech, a member of Roche Group (USA - CA - Switzerland)
Product: GDC-0310
Action
mechanism: Nav1.7 inhibitor
Disease: pain
Therapeutic area: CNS diseases - Neurological diseases
Country: USA
Trial
details: The purpose of this study is to evaluate the safety and tolerability of single and multiple orally administered doses of GDC-0310 in healthy participants. ( NCT02742779)
Latest
news: * On March 11, 2016, a Phase I trial sponsored by Genentech was published on the NIH website ClinicalTrials.gov for GDC-0310.
